PL3597038T3 - Humanizowane gryzonie wykazujące ekspresję łańcuchów ciężkich zawierających domeny vl - Google Patents

Humanizowane gryzonie wykazujące ekspresję łańcuchów ciężkich zawierających domeny vl

Info

Publication number
PL3597038T3
PL3597038T3 PL19191081T PL19191081T PL3597038T3 PL 3597038 T3 PL3597038 T3 PL 3597038T3 PL 19191081 T PL19191081 T PL 19191081T PL 19191081 T PL19191081 T PL 19191081T PL 3597038 T3 PL3597038 T3 PL 3597038T3
Authority
PL
Poland
Prior art keywords
domains
heavy chains
chains containing
express heavy
humanized rodents
Prior art date
Application number
PL19191081T
Other languages
English (en)
Inventor
Lynn Macdonald
Cagan Gurer
Karolina A Meagher
Sean Stevens
Andrew J Murphy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of PL3597038T3 publication Critical patent/PL3597038T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24046—Adamalysin (3.4.24.46)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Central Heating Systems (AREA)
  • Housing For Livestock And Birds (AREA)
PL19191081T 2012-02-01 2013-02-01 Humanizowane gryzonie wykazujące ekspresję łańcuchów ciężkich zawierających domeny vl PL3597038T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261593463P 2012-02-01 2012-02-01
US201261677538P 2012-07-31 2012-07-31
PCT/US2013/024295 WO2013116609A1 (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains
EP19191081.9A EP3597038B1 (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains
EP13704329.5A EP2809150B1 (en) 2012-02-01 2013-02-01 Humanized mice that express heavy chains containing vl domains

Publications (1)

Publication Number Publication Date
PL3597038T3 true PL3597038T3 (pl) 2021-11-08

Family

ID=47714588

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13704329T PL2809150T3 (pl) 2012-02-01 2013-02-01 Humanizowane myszy wykazujące ekspresję łańcuchów ciężkich zawierających domeny VL
PL19191081T PL3597038T3 (pl) 2012-02-01 2013-02-01 Humanizowane gryzonie wykazujące ekspresję łańcuchów ciężkich zawierających domeny vl

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL13704329T PL2809150T3 (pl) 2012-02-01 2013-02-01 Humanizowane myszy wykazujące ekspresję łańcuchów ciężkich zawierających domeny VL

Country Status (26)

Country Link
US (3) US20130212719A1 (pl)
EP (3) EP2809150B1 (pl)
JP (6) JP2015505477A (pl)
KR (2) KR20140123983A (pl)
CN (2) CN104202971B (pl)
AU (3) AU2013204758B2 (pl)
BR (1) BR112014018843B1 (pl)
CA (1) CA2863175A1 (pl)
CY (2) CY1122419T1 (pl)
DK (2) DK2809150T3 (pl)
ES (2) ES2753774T3 (pl)
HR (2) HRP20192218T1 (pl)
HU (2) HUE055610T2 (pl)
IL (3) IL233827A0 (pl)
LT (2) LT2809150T (pl)
ME (1) ME03611B (pl)
MX (2) MX2020003491A (pl)
NZ (5) NZ793447A (pl)
PL (2) PL2809150T3 (pl)
PT (2) PT3597038T (pl)
RS (2) RS62023B1 (pl)
RU (2) RU2664185C2 (pl)
SG (3) SG10201913428QA (pl)
SI (2) SI2809150T1 (pl)
SM (2) SMT202100401T1 (pl)
WO (1) WO2013116609A1 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2725169A1 (en) * 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
DK3028565T3 (da) 2009-07-08 2017-11-13 Kymab Ltd Dyremodeller og terapeutiske molekyler
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
EP2947151A1 (en) 2010-08-02 2015-11-25 Regeneron Pharmaceuticals, Inc. Binding proteins comprising vl domains
HRP20241480T1 (hr) 2011-08-05 2025-01-03 Regeneron Pharmaceuticals, Inc. Humanizirani miševi univerzalnog lakog lanca
CN103945689B (zh) 2011-09-19 2016-10-19 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
SG11201403326VA (en) 2011-12-20 2014-07-30 Regeneron Pharma Humanized light chain mice
NZ793447A (en) * 2012-02-01 2024-05-31 Regeneron Pharma Humanized rodents that express heavy chains containing vl domains
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
DK2858487T3 (da) 2012-06-12 2020-01-20 Regeneron Pharma Humaniserede ikke-humane dyr med begrænsede immunoglobulin-tungkæde-loci
CN109769752A (zh) 2013-02-20 2019-05-21 瑞泽恩制药公司 具有修饰的免疫球蛋白重链序列的非人类动物
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
SG11201602236SA (en) 2013-10-01 2016-04-28 Kymab Ltd Animal models and therapeutic molecules
RU2016141123A (ru) 2014-03-21 2018-04-23 Регенерон Фармасьютикалз, Инк. Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики
RU2016141307A (ru) 2014-03-21 2018-04-24 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
HK1250038A1 (zh) * 2015-03-19 2018-11-23 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
CA2981077A1 (en) * 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
JP2019513415A (ja) * 2016-04-04 2019-05-30 イーティーエッチ チューリッヒ タンパク質産生及びライブラリー生成のための哺乳類細胞株
US20170332610A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
CN110719732B (zh) * 2017-03-30 2022-11-18 犹他州立大学 表达蜘蛛丝的转基因蚕
RS63772B1 (sr) * 2017-12-05 2022-12-30 Regeneron Pharma Miševi koji imaju modifikovani lambda laki lanac imunoglobulina i njihove upotrebe
CA3093995A1 (en) * 2018-03-24 2019-10-03 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
IL318469A (en) * 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
CA3187680A1 (en) 2020-09-11 2022-03-17 Yashu Liu Identification and production of antigen-specific antibodies
AU2021400584A1 (en) 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CN114645042A (zh) * 2020-12-18 2022-06-21 中国食品药品检定研究院 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法
CN114196626A (zh) * 2022-02-16 2022-03-18 北京国卫生物科技有限公司 脐带间充质干细胞及其分离培养扩增方法
WO2025145264A1 (zh) * 2024-01-02 2025-07-10 江苏集萃药康生物科技股份有限公司 产生人源化抗体的动物模型及其构建方法
CN121065267A (zh) * 2024-06-04 2025-12-05 赛业（苏州）生物科技有限公司 用于制备四元固定轻链的基因修饰的啮齿动物及其制备方法
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
CN1468250A (zh) * 2000-08-03 2004-01-14 ��ķһ����˹��̹ 在转基因动物中产生人源化抗体
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101016543A (zh) * 2000-11-17 2007-08-15 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
EP1458852B1 (en) * 2001-12-21 2011-03-09 ThromboGenics N.V. Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability and for the culture of adult stem cells
US20050246782A1 (en) * 2002-03-22 2005-11-03 Origen Therapeutics Transgenic aves producing human polyclonal antibodies
AU2004257292A1 (en) * 2003-07-15 2005-01-27 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
WO2006047367A2 (en) * 2004-10-22 2006-05-04 Therapeutic Human Polyclonals, Inc. Suppression of endogenous immunoglubolin expression in non-human transgenic animals
CA2638774C (en) * 2006-03-31 2015-11-24 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
ATE536374T1 (de) * 2006-09-01 2011-12-15 Therapeutic Human Polyclonals Inc Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren
CA2697448C (en) * 2007-08-30 2019-06-11 The Burnet Institute Dendritic cell marker and uses thereof
SG193868A1 (en) * 2007-09-26 2013-10-30 Chugai Pharmaceutical Co Ltd Modified antibody constant region
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
CA2725169A1 (en) * 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
DK3456192T3 (da) * 2008-06-27 2025-11-24 Merus Nv Anvendelse af antistof-producerende murine pattedyr for at generere antistoffer med høj affinitet
AU2009287165A1 (en) * 2008-08-29 2010-03-04 Symphogen A/S Method for cloning avian-derived antibodies
WO2010091182A2 (en) * 2009-02-04 2010-08-12 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
DK3028565T3 (da) * 2009-07-08 2017-11-13 Kymab Ltd Dyremodeller og terapeutiske molekyler
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
AU2011266843C9 (en) * 2010-06-17 2018-03-01 Kymab Limited Animal models and therapeutic molecules
EP2947151A1 (en) * 2010-08-02 2015-11-25 Regeneron Pharmaceuticals, Inc. Binding proteins comprising vl domains
EP2578688B2 (en) * 2011-02-25 2023-02-08 Regeneron Pharmaceuticals, Inc. ADAM6 mice
HRP20241480T1 (hr) * 2011-08-05 2025-01-03 Regeneron Pharmaceuticals, Inc. Humanizirani miševi univerzalnog lakog lanca
SG11201403326VA (en) * 2011-12-20 2014-07-30 Regeneron Pharma Humanized light chain mice
NZ793447A (en) * 2012-02-01 2024-05-31 Regeneron Pharma Humanized rodents that express heavy chains containing vl domains
DK2858487T3 (da) * 2012-06-12 2020-01-20 Regeneron Pharma Humaniserede ikke-humane dyr med begrænsede immunoglobulin-tungkæde-loci
SG10201913483XA (en) * 2016-11-04 2020-03-30 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain locus

Also Published As

Publication number Publication date
RU2018122695A3 (pl) 2021-10-06
BR112014018843A2 (pt) 2017-07-04
NZ719228A (en) 2022-08-26
HRP20210987T1 (hr) 2021-09-17
HRP20192218T1 (hr) 2020-03-06
HUE055610T2 (hu) 2021-12-28
RS59699B1 (sr) 2020-01-31
RU2018122695A (ru) 2019-03-06
US20210368751A1 (en) 2021-12-02
RU2014133653A (ru) 2016-03-20
RU2770016C2 (ru) 2022-04-14
EP2809150B1 (en) 2019-09-18
EP3597038B1 (en) 2021-04-21
US20170094955A1 (en) 2017-04-06
LT3597038T (lt) 2021-05-25
NZ810648A (en) 2025-11-28
JP6942757B2 (ja) 2021-09-29
NZ793447A (en) 2024-05-31
WO2013116609A1 (en) 2013-08-08
PL2809150T3 (pl) 2020-04-30
IL268675B (en) 2020-11-30
DK3597038T3 (da) 2021-06-28
JP2018075041A (ja) 2018-05-17
JP2021137030A (ja) 2021-09-16
HK1202771A1 (en) 2015-10-09
SG11201404477YA (en) 2014-08-28
SI2809150T1 (sl) 2019-11-29
AU2013204758B2 (en) 2015-07-23
JP2015505477A (ja) 2015-02-23
US20130212719A1 (en) 2013-08-15
RS62023B1 (sr) 2021-07-30
JP2023014242A (ja) 2023-01-26
IL261280A (en) 2018-10-31
PT2809150T (pt) 2019-12-09
JP7525579B2 (ja) 2024-07-30
CN104202971B (zh) 2016-07-06
AU2015246154B2 (en) 2017-11-23
KR20140123983A (ko) 2014-10-23
IL261280B (en) 2019-08-29
BR112014018843B1 (pt) 2024-02-20
SMT201900685T1 (it) 2020-01-14
NZ627977A (en) 2016-06-24
EP3597038A1 (en) 2020-01-22
ME03611B (me) 2020-07-20
NZ734504A (en) 2022-10-28
CY1122419T1 (el) 2021-01-27
ES2753774T3 (es) 2020-04-14
MX2019002517A (es) 2019-06-17
CN106117364B (zh) 2021-08-31
HUE046744T2 (hu) 2020-03-30
IL233827A0 (en) 2014-09-30
JP2023168590A (ja) 2023-11-24
AU2017251848B2 (en) 2020-02-20
AU2015246154A1 (en) 2015-11-12
CY1124361T1 (el) 2022-07-22
AU2017251848A1 (en) 2017-11-16
JP2019170395A (ja) 2019-10-10
EP3912465A1 (en) 2021-11-24
CA2863175A1 (en) 2013-08-08
SI3597038T1 (sl) 2021-07-30
IL268675A (en) 2019-10-31
PT3597038T (pt) 2021-05-10
CN104202971A (zh) 2014-12-10
ES2870703T3 (es) 2021-10-27
LT2809150T (lt) 2019-10-25
SG10201913428QA (en) 2020-03-30
SG10201606256TA (en) 2016-09-29
JP7187615B2 (ja) 2022-12-12
RU2664185C2 (ru) 2018-08-15
MX2020003491A (es) 2022-10-25
DK2809150T3 (da) 2019-12-09
BR112014018843A8 (pt) 2019-01-29
KR20190006029A (ko) 2019-01-16
MX373286B (es) 2020-05-20
SMT202100401T1 (it) 2021-09-14
JP6698718B2 (ja) 2020-05-27
AU2013204758A1 (en) 2013-08-15
CN106117364A (zh) 2016-11-16
EP2809150A1 (en) 2014-12-10

Similar Documents

Publication Publication Date Title
IL268675B (en) Humanized rodents expressing heavy chains comprising vl complexes
IL268674A (en) Rodents with humanized IL-7
ZA201407272B (en) Anti-baff-anti-il-17 bispecific antibodies
PL3058134T3 (pl) Pozakomórkowe polimery z granulowanego osadu ściekowego jako środki zaklejające
GB2511165B (en) Multi-sash closure system
SI2746185T1 (sl) Zaporni šarnir
ZA201306526B (en) Roll-open closure
AU342768S (en) Latch for lunchbox
GB201321568D0 (en) Chain stopper
ZA201301102B (en) Closure arrangement
AU346180S (en) Spout
GB201214914D0 (en) Eye cab